Update. Re investor-led financing
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes
Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, announces that it has agreed to extend its Bookbuild process to midday on 4 December 2023, following indications of strong demand from Existing Shareholders to participate in its proposed Placing (as announced on 30 November 2023).
Further announcements will be made in due course.
Save as otherwise defined, capitalised terms used in this announcement have the meanings given to them in the announcement released by the Company on 30 November 2023.
Ondine Biomedical Inc.
| Angelika Vance, Corporate Communications | +001 (604) 838 2702 |
| Singer Capital Markets (Nominated Adviser and Joint Broker) | |
| Aubrey Powell, Asha Chotai, Sam Butcher | +44 (0)20 7496 3000 |
| RBC Capital Markets (Joint Broker) | |
| Rupert Walford, Kathryn Deegan | +44 (0)20 7653 4000 |
| Vane Percy & Roberts (Media Contact) | |
| Simon Vane Percy, Amanda Bernard | +44 (0)77 1000 5910 |
UK Product Governance Requirements
EU Product Governance Requirements
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.